Introduction
Methicillin-susceptible Staphylococcus epidermidis (MSSE) and methicillin-resistant S. epidermidis (MRSE) isolates were inhibited by quinupristin-dalfopristin at ^0.5 mg/L; quinupristin-dalfopristin was four times more active than vancomycin and teicoplanin. All other drugs inhibited MSSE at low concentrations, but MICs for MRSE were more than ten-fold higher. All isolates of Staphylococcus haemolyticus were inhibited by quinupristin-dalfopristin at =sl mg/L; the MICs of vancomycin and teicoplanin were two to eight times higher. The other drugs inhibited S. haemolyticus at varying concentrations, rifampicin at the lowest.
Entero cocci
Enterococcus faecalis isolates, including highly gentamicin-resistant strains, were inhibited by quinupristindalfopristin at 8 mg/L, by vancomycin at 4 mg/L and by teicoplanin at 0.25 mg/L. All strains were inhibited by imipenem at 4 mg/L, about 50% of the susceptible E. faecalis strains were inhibited by the quinolones at 1 mg/L. The other drugs showed moderate to poor effect. . sanguis and S. mitis isolates were from patients with endocarditis. In comparative studies the activity of quinu pristin-dalfopristin against some viridans streptococci was similar to that of macrolides.3,7 This study showed that quinupristin-dalfopristin, imipenem and meropenem could inhibit all 77 strains tested at very low concentra tions, whereas not all strains were susceptible to macrolides or rifampicin. Carbapenems and quinu pristin-dalfopristin may therefore be interesting alterna tives as new, potent, non-toxic combinations for the treatment of endocarditis.
We have found that most E. faecium strains were resis tant to macrolides, quinolones and carbapenems.8 We also observed an increase in MIC with time: 100% were susceptible before ciprofloxacin was introduced6 compared with 56% at present. Like others, we found that E. faecalis was less susceptible to quinupristindalfopristin than E. faecium,3,9 although 80% of E. fae calis and 55% of the highly resistant strains were sus ceptible to ^4 mg/L. No vancomycin-resistant isolates were found, so vancomycin and teicoplanin may remain first choice agents for enterococcal infections and quinu pristin-dalfopristin may be kept for the treatment of vancomycin-resistant isolates.
In conclusion, quinupristin-dalfopristin shows promis ing in-vitro activity and may be a welcome drug in the therapy of methicillin-resistant staphylococcal infections and infections by viridans streptococci and resistant enterococci.
